New Leader Appointed: Jim Bartel Takes Over as CEO at Vantage MedTech
Vantage MedTech, a healthcare-focused company known for its accelerated product development timelines and flexible manufacturing approach, has announced a significant leadership change. Jim Bartel has been appointed as the new Chief Executive Officer (CEO) of the company.
Bartel brings over 25 years of leadership experience in the medical device and contract manufacturing industries to his new role. He holds a B.A. in Economics and Management from Hartwick College and an M.B.A. from the University of St. Thomas, Opus College of Business.
Throughout his career, Bartel has demonstrated exceptional leadership qualities, particularly in managing marketing, business development, and sales teams. He spent four years at Stratasys as VP and General Manager of their rapid prototyping business unit. Most recently, he served as CEO and Board Member of Waltek, Inc. and President of Spectralytics, Inc.
Trevor Wahlbrink, Partner at Ampersand Capital Partners, expressed his excitement about Bartel's appointment. Wahlbrink praised Bartel's deep understanding of product development and building high-performing teams, which he believes will be invaluable in driving Vantage MedTech's growth and success.
Ampersand Capital Partners, a middle market private equity firm with $3 billion of assets under management, is the backing force behind Vantage MedTech. The firm, which has offices in Boston, MA, and Amsterdam, Netherlands, is dedicated to growth-oriented investments in the healthcare sector.
Vantage MedTech's services span from feasibility support and product development to prototyping, clinical and commercial manufacturing, and after-market services. The company's facilities are located in Moonachie, New Jersey, and Lenexa, Kansas. Vantage MedTech partners with both MedTech start-ups and large medical device companies.
Upon his appointment, Bartel expressed his gratitude for the opportunity and highlighted Vantage's team of 150+ medical device engineers. He emphasised the company's commitment to comprehensive design and manufacturing services for medical technologies.
For more information about Vantage MedTech, visit VantageMedTech.com or connect on LinkedIn.
- The news of Jim Bartel's appointment as CEO of Vantage MedTech has been met with excitement, as he brings over two decades of leadership experience in the medical device and contract manufacturing industries.
- Ampersand Capital Partners, a significant player in the healthcare sector with $3 billion of assets under management, is backing Vantage MedTech and believes Bartel's expertise in product development and team building will be instrumental in the company's growth.
- In his new role, Bartel will lead Vantage MedTech, a company renowned for its accelerated product development timelines and flexible manufacturing approach, as they continue to provide comprehensive design and manufacturing services for medical technologies.
- industry professionals and investors are closely watching the impact of Bartel's leadership on Vantage MedTech's financial performance and its continued partnerships with both MedTech start-ups and large medical device companies.
